- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Farmington Hills Today
By the People, for the People
Opus Genetics (IRD) to Release Earnings on Monday
Analysts expect the company to announce earnings of ($0.10) per share and revenue of $3.35 million for the quarter.
Mar. 23, 2026 at 6:14am
Got story updates? Submit your updates here. ›
Opus Genetics (NASDAQ:IRD), a clinical-stage ophthalmic biopharmaceutical company focused on developing therapies for refractive and retinal eye disorders, is expected to announce its quarterly earnings results before the market opens on Monday, March 30.
Why it matters
As a publicly traded company, Opus Genetics' earnings report will provide investors with key financial data and insights into the company's performance and future prospects in the competitive ophthalmic drug development space.
The details
Analysts are forecasting Opus Genetics to report a loss of $0.10 per share on revenue of $3.35 million for the quarter. The company's stock has seen significant volatility over the past year, trading between $0.65 and $5.30 per share.
- Opus Genetics will release its earnings before the market opens on Monday, March 30, 2026.
The players
Opus Genetics
A clinical-stage ophthalmic biopharmaceutical company that focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders.
George Magrath
The CEO of Opus Genetics.
Cam Gallagher
A director at Opus Genetics who recently acquired 83,000 shares of the company's stock.
What’s next
Investors will be closely watching Opus Genetics' earnings report on Monday to gauge the company's financial performance and outlook for the future.
The takeaway
Opus Genetics' upcoming earnings release will provide important financial data and insights into the company's progress in developing innovative ophthalmic treatments, which could impact investor sentiment and the stock's valuation.
